NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
Celgene
Ipsen
Hutchmed
Hutchmed
Bayer
Celgene
Takeda
AbbVie
Takeda
Seagen Inc.
AbbVie
Millennium Pharmaceuticals, Inc.